Company:  ARRAY BIOPHARMA INC (ARRY)
Form Type:  8-K
Filing Date:  6/17/2013 
CIK:  0001100412 
Address:  3200 WALNUT STREET 
City, State, Zip:  BOULDER, Colorado 80301 
Telephone:  (303) 381-6600 
Fiscal Year:  06/30 
Last Trade
Last Trade: 
$4.09  
Change: 
0.29 (7.63%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$513.12M
Description of Business
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and is generating data to support our upcoming Phase 3 / pivotal trial decisions. Novartis International Pharmaceutical Ltd. began a Phase 3 trial evaluating Array-invented MEK162 in NRAS-mutant melanoma in July 2013 and expects to begin a Phase 3 trial in BRAF-mutant melanoma in 2013. In addition, Array began a Phase 3 trial evaluating MEK162 in low-grade serous ovarian cancer under the License Agreement with Novartis in June 2013. AstraZeneca, PLC began a pivotal trial with Array-invented selumetinib in thyroid cancer in May 2013 and expects to begin a Phase 3 trial in non-small cell lung cancer in 2013. Three other Array-invented drugs are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013.
Register for EDGAR Pro and access this filing in:     
  FORM 8-K
    SECTION 8 OTHER EVENTS
      Item 8.01 Other Events.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01 Financial Statements and Exhibits.
    SIGNATURE
    EXHIBIT INDEX
  EXHIBIT 99.1
BROKERAGE PARTNERS